Manufacturing (industry group 28), latest filing in July 2026

Aemetis Inc

Aemetis Inc has 1 Schedule 13D or 13G filing on record since 2026-07-27. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Aemetis Inc by CUSIP 00770K202 and gives its principal executive office as 20400 Stevens Creek Blvd., Suite 700, Cupertino, CA 95014 (SCHEDULE 13G, 2026-07-27).

Swipe the table sideways to see every column.

Alto Ingredients, Inc.

Alto Ingredients, Inc. has 2 Schedule 13D or 13G filings on record since 2026-02-13. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Alto Ingredients, Inc. by CUSIP 021513106 and gives its principal executive office as 1300 South Second Street, Pekin, IL 61554 (SCHEDULE 13G, 2026-07-27).

Swipe the table sideways to see every column.

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc has 3 Schedule 13D or 13G filings on record since 2025-10-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Amphastar Pharmaceuticals Inc by CUSIP 03209R103 and gives its principal executive office as 11570 6th Street, Rancho Cucamonga (SCHEDULE 13G, 2026-07-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Anavex Life Sciences Corp

Anavex Life Sciences Corp has 2 Schedule 13D or 13G filings on record since 2026-03-26. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Anavex Life Sciences Corp by CUSIP 032797300 and gives its principal executive office as 51 West 52nd Street, 7th Floor, New York, NY 10019 (SCHEDULE 13G, 2026-07-31).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Ani Pharmaceuticals Inc

Ani Pharmaceuticals Inc has 5 Schedule 13D or 13G filings on record since 2025-08-22. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Ani Pharmaceuticals Inc by CUSIP 00182C103 and gives its principal executive office as 104 Carnegie Center Drive, Suite 300, Princeton, NJ 08540 (SCHEDULE 13G/A, 2026-07-27).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Axsome Therapeutics, Inc. by CUSIP 05464T104 and gives its principal executive office as ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY 10007 (SCHEDULE 13G/A, 2026-07-27).

Swipe the table sideways to see every column.

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2026-02-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Black Diamond Therapeutics, Inc. by CUSIP 09203E105 and gives its principal executive office as 245 First Street, 18th Floor, CAMBRIDGE, MA 02142 (SCHEDULE 13G, 2026-07-27).

Swipe the table sideways to see every column.

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. has 2 Schedule 13D or 13G filings on record since 2025-07-16. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: about 87 jobs, latest 2026-10-06 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Caribou Biosciences, Inc. by CUSIP 142038108 and gives its principal executive office as 2929 7TH STREET, SUITE 105, BERKELEY, CA 94710 (SCHEDULE 13G, 2026-07-27).

Swipe the table sideways to see every column.

Coherus Oncology, Inc.

Coherus Oncology, Inc. has 9 Schedule 13D or 13G filings on record since 2025-11-04. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Coherus Oncology, Inc. by CUSIP 19249H103 and gives its principal executive office as 333 Twin Dolphin Drive, Suite 600, REDWOOD CITY, CA 94065 (SCHEDULE 13G, 2026-07-27).

Swipe the table sideways to see every column.

CSW Industrials Inc

CSW Industrials Inc has 8 Schedule 13D or 13G filings on record since 2025-10-17. 3 holders' latest filing reports 5% or more of com. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies CSW Industrials Inc by CUSIP 126402106 and gives its principal executive office as 5420 Lyndon B Johnson Freeway; Suite 500, Dallas, TX 75240 (SCHEDULE 13G/A, 2026-07-13).

Swipe the table sideways to see every column.

Ecolab Inc.

Ecolab Inc. has 3 Schedule 13D or 13G filings on record since 2026-03-26. 2 holders' latest filing reports 5% or more of common stock, $1.00 par value. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2026-02-10 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Ecolab Inc. by CUSIP 278865100 and gives its principal executive office as 1 ECOLAB PLACE, SAINT PAUL, MN 55102 (SCHEDULE 13G, 2026-07-16).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2025-10-07. 2 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Elicio Therapeutics, Inc. by CUSIP 28657F103 and gives its principal executive office as 451 D STREET, 5TH FLOOR, BOSTON, MA 02210 (SCHEDULE 13G, 2026-07-16).

Swipe the table sideways to see every column.

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Eton Pharmaceuticals, Inc. by CUSIP 29772L108 and gives its principal executive office as 21925 W. Field Parkway, Suite 235, Deer Park, IL 60010 (SCHEDULE 13G/A, 2026-11-06).

8.54% Based on 28,583,135 shares of Common Stock outstanding as of August 11, 2026, as reported by the Issuer in its Form 10-Q filed on August 13, 2026.Opaleye Management Inc., SCHEDULE 13G/A, 2026-11-06

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-17. 3 holders' latest filing reports 5% or more of class a stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Ginkgo Bioworks Holdings, Inc. by CUSIP 37611X209 and gives its principal executive office as 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON, MA 02210 (SCHEDULE 13G/A, 2026-07-30).

Swipe the table sideways to see every column.

Haleon Plc

Haleon Plc has 2 Schedule 13D or 13G filings on record since 2026-02-10. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Haleon Plc by CUSIP G4232K100 and gives its principal executive office as BUILDING 5, FIRST FLOOR, THE HEIGHTS, WEYBRIDGE (SCHEDULE 13G/A, 2026-07-28).

Swipe the table sideways to see every column.

HB Fuller Co

HB Fuller Co has 5 Schedule 13D or 13G filings on record since 2025-10-17. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies HB Fuller Co by CUSIP 359694106 and gives its principal executive office as 1200 Willow Lake Blvd, PO Box 64683, Vadnais Heights, Saint Paul (SCHEDULE 13G, 2026-07-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

HST Global, Inc.

HST Global, Inc. has 2 Schedule 13D or 13G filings on record since 2025-11-10. 1 holder's latest filing reports 5% or more of common. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies HST Global, Inc. by CUSIP 40432E202 and gives its principal executive office as 509 OLD GREAT NECK ROAD, SUITE 105, VIRGINIA BEACH, VA 23454 (SCHEDULE 13D, 2026-07-23).

43,441,573 common shares were purchased pursuant to a shareholder's rights offering for $156,389.66 which consisted of cash and converting of indebtedness, funded from personal funds. The transaction represented a 1 for 1 rights purchase and did not change the percentage ownership of the acquirer.Field Michael L, SCHEDULE 13D, 2026-07-23

Field Michael L

The purpose was for investment related to a shareholder's rights offering.Item 4 of the SCHEDULE 13D filed 2026-07-23

Swipe the table sideways to see every column.

Immuneering Corp

Immuneering Corp has 6 Schedule 13D or 13G filings on record since 2025-10-03. 4 holders' latest filing reports 5% or more of class a stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Immuneering Corp by CUSIP 45254E107 and gives its principal executive office as 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA 02142 (SCHEDULE 13G, 2026-07-28).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Nexentis Technologies Inc.

Nexentis Technologies Inc. has 6 Schedule 13D or 13G filings on record since 2025-10-24. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Nexentis Technologies Inc. by CUSIP 80512Q501 and gives its principal executive office as HaPardes 134 (Meshek Sander), Neve Yarak (SCHEDULE 13G/A, 2026-07-15).

Swipe the table sideways to see every column.

Niagen Bioscience, Inc.

Niagen Bioscience, Inc. has 3 Schedule 13D or 13G filings on record since 2025-10-31. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Niagen Bioscience, Inc. by CUSIP 171077407 and gives its principal executive office as 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA 90024 (SCHEDULE 13G, 2026-07-29).

Swipe the table sideways to see every column.

Nutrien Ltd

Nutrien Ltd has 4 Schedule 13D or 13G filings on record since 2025-10-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Nutrien Ltd by CUSIP 67077M108 and gives its principal executive office as 211 19th St E, Suite 1700, Saskatoon (SCHEDULE 13G, 2026-07-31).

Swipe the table sideways to see every column.

Nuvalent, Inc.

Nuvalent, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-17. 1 holder's latest filing reports 5% or more of class a common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Nuvalent, Inc. by CUSIP 670703107 and gives its principal executive office as One Broadway, 14th Floor, Cambridge, MA 02142 (SCHEDULE 13G/A, 2026-07-17).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Omeros Corp

Omeros Corp has 5 Schedule 13D or 13G filings on record since 2025-10-31. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Omeros Corp by CUSIP 682143102 and gives its principal executive office as 201 ELLIOTT AVENUE WEST, SEATTLE, WA 98119 (SCHEDULE 13G/A, 2026-07-29).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Opko Health, Inc.

Opko Health, Inc. has 3 Schedule 13D or 13G filings on record since 2025-07-09. 2 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Opko Health, Inc. by CUSIP 68375N103 and gives its principal executive office as 4400 BISCAYNE BLVD., MIAMI, FL 33137 (SCHEDULE 13D/A, 2026-07-01).

Swipe the table sideways to see every column.

Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-13. 3 holders' latest filing reports 5% or more of common stock sh. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Prestige Consumer Healthcare Inc. by CUSIP 74112D101 and gives its principal executive office as 660 WHITE PLAINS RD, TARRYTOWN, NY 10591 (SCHEDULE 13G/A, 2026-07-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc has 6 Schedule 13D or 13G filings on record since 2025-08-14. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Rocket Pharmaceuticals Inc by CUSIP 77313F106 and gives its principal executive office as 430 East 29th Street, Suite 1040, New York, NY 10016 (SCHEDULE 13G/A, 2026-10-30).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. has 4 Schedule 13D or 13G filings on record since 2025-10-01. 2 holders' latest filing reports 5% or more of american depository shares, each representing 4,000 ordinary shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Scinai Immunotherapeutics Ltd. by CUSIP 09073Q203 and gives its principal executive office as JERUSALEM BIOPARK, 2ND FLOOR, HADASSAH EIN KEREM CAMPUS, JERUSALEM (SCHEDULE 13G/A, 2026-07-09).

Swipe the table sideways to see every column.

Serina Therapeutics, Inc.

Serina Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2026-05-04. 2 holders' latest filing reports 5% or more of common stock, par value, $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Serina Therapeutics, Inc. by CUSIP 81751A108 and gives its principal executive office as 601 Genome Way, Suite 2001, Huntsville, AL 35806 (SCHEDULE 13G/A, 2026-11-03).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Solstice Advanced Materials Inc

Solstice Advanced Materials Inc has 9 Schedule 13D or 13G filings on record since 2025-11-05. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Solstice Advanced Materials Inc by CUSIP 83443Q103 and gives its principal executive office as 115 Tabor Road, Morris Plains, NJ 07950 (SCHEDULE 13G/A, 2026-10-30).

Swipe the table sideways to see every column.

Trulieve Cannabis Corp.

Trulieve Cannabis Corp. has 2 Schedule 13D or 13G filings on record since 2025-12-18. 2 holders' latest filing reports 5% or more of subordinate voting shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Trulieve Cannabis Corp. by CUSIP 89788C104 and gives its principal executive office as 3494 Martin Hurst Road, Tallahassee, FL 32312 (SCHEDULE 13G, 2026-07-08).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc has 4 Schedule 13D or 13G filings on record since 2026-01-30. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Xeris Biopharma Holdings Inc by CUSIP 98422E103 and gives its principal executive office as 180 North LaSalle Street, Suite 1800, Chicago, IL 60601 (SCHEDULE 13G/A, 2026-10-30).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Zoetis Inc

Zoetis Inc has 5 Schedule 13D or 13G filings on record since 2026-01-07. 3 holders' latest filing reports 5% or more of class a stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Zoetis Inc by CUSIP 98978V103 and gives its principal executive office as 10 SYLVAN WAY, PARSIPPANY, NJ 07054 (SCHEDULE 13G/A, 2026-07-30).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.